182 related articles for article (PubMed ID: 8811201)
1. Evaluation of Cidofovir (HPMPC, GS-504) against adenovirus type 5 infection in vitro and in a New Zealand rabbit ocular model.
de Oliveira CB; Stevenson D; LaBree L; McDonnell PJ; Trousdale MD
Antiviral Res; 1996 Jul; 31(3):165-72. PubMed ID: 8811201
[TBL] [Abstract][Full Text] [Related]
2. Antiviral prophylaxis with twice daily topical cidofovir protects against challenge in the adenovirus type 5/New Zealand rabbit ocular model.
Romanowski EG; Yates KA; Gordon YJ
Antiviral Res; 2001 Dec; 52(3):275-80. PubMed ID: 11675144
[TBL] [Abstract][Full Text] [Related]
3. Topical HPMPC inhibits adenovirus type 5 in the New Zealand rabbit ocular replication model.
Gordon YJ; Romanowski EG; Araullo-Cruz T
Invest Ophthalmol Vis Sci; 1994 Nov; 35(12):4135-43. PubMed ID: 7960596
[TBL] [Abstract][Full Text] [Related]
4. The cotton rat model for adenovirus ocular infection: antiviral activity of cidofovir.
Kaneko H; Mori S; Suzuki O; Iida T; Shigeta S; Abe M; Ohno S; Aoki K; Suzutani T
Antiviral Res; 2004 Jan; 61(1):63-6. PubMed ID: 14670595
[TBL] [Abstract][Full Text] [Related]
5. The antiviral resistance and replication of cidofovir-resistant adenovirus variants in the New Zealand White rabbit ocular model.
Romanowski EG; Gordon YJ; Araullo-Cruz T; Yates KA; Kinchington PR
Invest Ophthalmol Vis Sci; 2001 Jul; 42(8):1812-5. PubMed ID: 11431446
[TBL] [Abstract][Full Text] [Related]
6. Topical corticosteroids reverse the antiviral effect of topical cidofovir in the Ad5-inoculated New Zealand rabbit ocular model.
Romanowski EG; Araullo-Cruz T; Gordon YJ
Invest Ophthalmol Vis Sci; 1997 Jan; 38(1):253-7. PubMed ID: 9019458
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of topical cidofovir on multiple adenoviral serotypes in the New Zealand rabbit ocular model.
Romanowski EG; Gordon YJ
Invest Ophthalmol Vis Sci; 2000 Feb; 41(2):460-3. PubMed ID: 10670476
[TBL] [Abstract][Full Text] [Related]
8. Effects of diclofenac or ketorolac on the inhibitory activity of cidofovir in the Ad5/NZW rabbit model.
Romanowski EG; Gordon YJ
Invest Ophthalmol Vis Sci; 2001 Jan; 42(1):158-62. PubMed ID: 11133861
[TBL] [Abstract][Full Text] [Related]
9. The in vitro and in vivo evaluation of ddC as a topical antiviral for ocular adenovirus infections.
Romanowski EG; Yates KA; Gordon YJ
Invest Ophthalmol Vis Sci; 2009 Nov; 50(11):5295-9. PubMed ID: 19516011
[TBL] [Abstract][Full Text] [Related]
10. Isolation of human adenovirus type 5 variants resistant to the antiviral cidofovir.
Gordon YJ; Araullo-Cruz TP; Johnson YF; Romanowski EG; Kinchington PR
Invest Ophthalmol Vis Sci; 1996 Dec; 37(13):2774-8. PubMed ID: 8977495
[TBL] [Abstract][Full Text] [Related]
11. Pretreatment with topical 0.1% (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine inhibits adenovirus type 5 replication in the New Zealand rabbit ocular model.
Gordon YJ; Romanowski E; Araullo-Cruz T; De Clercq E
Cornea; 1992 Nov; 11(6):529-33. PubMed ID: 1334824
[TBL] [Abstract][Full Text] [Related]
12. N-chlorotaurine is an effective antiviral agent against adenovirus in vitro and in the Ad5/NZW rabbit ocular model.
Romanowski EG; Yates KA; Teuchner B; Nagl M; Irschick EU; Gordon YJ
Invest Ophthalmol Vis Sci; 2006 May; 47(5):2021-6. PubMed ID: 16639011
[TBL] [Abstract][Full Text] [Related]
13. Inhibitory effect of (S)-HPMPC, (S)-HPMPA, and 2'-nor-cyclic GMP on clinical ocular adenoviral isolates is serotype-dependent in vitro.
Gordon YJ; Romanowski E; Araullo-Cruz T; Seaberg L; Erzurum S; Tolman R; De Clercq E
Antiviral Res; 1991 Jul; 16(1):11-6. PubMed ID: 1776874
[TBL] [Abstract][Full Text] [Related]
14. Clinical and antiviral efficacy of an ophthalmic formulation of dexamethasone povidone-iodine in a rabbit model of adenoviral keratoconjunctivitis.
Clement C; Capriotti JA; Kumar M; Hobden JA; Foster TP; Bhattacharjee PS; Thompson HW; Mahmud R; Liang B; Hill JM
Invest Ophthalmol Vis Sci; 2011 Jan; 52(1):339-44. PubMed ID: 20702820
[TBL] [Abstract][Full Text] [Related]
15. An ocular model of Adenovirus type 5 infection in the rabbit.
De Hauwere B; Lutz A; Maudgal PC; Neyts J; de Clercq E
Bull Soc Belge Ophtalmol; 1995; 259():33-42. PubMed ID: 8936772
[TBL] [Abstract][Full Text] [Related]
16. Studies of adenovirus-induced eye disease in the rabbit model.
Trousdale MD; Nóbrega R; Wood RL; Stevenson D; dos Santos PM; Klein D; McDonnell PJ
Invest Ophthalmol Vis Sci; 1995 Dec; 36(13):2740-8. PubMed ID: 7499096
[TBL] [Abstract][Full Text] [Related]
17. Cidofovir and brincidofovir reduce the pathology caused by systemic infection with human type 5 adenovirus in immunosuppressed Syrian hamsters, while ribavirin is largely ineffective in this model.
Tollefson AE; Spencer JF; Ying B; Buller RM; Wold WS; Toth K
Antiviral Res; 2014 Dec; 112():38-46. PubMed ID: 25453340
[TBL] [Abstract][Full Text] [Related]
18. [Antiviral effect of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine on adenovirus].
Nakajima H; Goto M; Shimada Y; Nagamoto Y; Ishiko H; Inagawa W; Itoh N; Uchio E; Ohno S; Aoki K
Nippon Ganka Gakkai Zasshi; 2000 Feb; 104(2):77-81. PubMed ID: 10714154
[TBL] [Abstract][Full Text] [Related]
19. Comparative antiviral efficacies of cidofovir, trifluridine, and acyclovir in the HSV-1 rabbit keratitis model.
Romanowski EG; Bartels SP; Gordon YJ
Invest Ophthalmol Vis Sci; 1999 Feb; 40(2):378-84. PubMed ID: 9950596
[TBL] [Abstract][Full Text] [Related]
20. Sequence changes in the human adenovirus type 5 DNA polymerase associated with resistance to the broad spectrum antiviral cidofovir.
Kinchington PR; Araullo-Cruz T; Vergnes JP; Yates K; Gordon YJ
Antiviral Res; 2002 Oct; 56(1):73-84. PubMed ID: 12323401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
